Medpace (NASDAQ:MEDP) Releases FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 17.970-18.320 for the period, compared to the consensus earnings per share estimate of 17.680. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Price Performance

Shares of MEDP stock traded up $4.65 during mid-day trading on Friday, hitting $658.61. 53,088 shares of the stock traded hands, compared to its average volume of 331,522. The stock has a market cap of $18.38 billion, a P/E ratio of 38.57, a P/E/G ratio of 2.96 and a beta of 1.18. The stock’s fifty day moving average is $609.84 and its two-hundred day moving average is $536.74. Medpace has a 52-week low of $373.00 and a 52-week high of $684.52.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.44 by $0.40. The firm had revenue of $716.00 million for the quarter, compared to the consensus estimate of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 104.17%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.86 EPS. As a group, equities analysts forecast that Medpace will post 17.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on MEDP. Robert W. Baird set a $699.00 price objective on Medpace in a report on Friday. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Barclays upped their target price on Medpace from $625.00 to $675.00 and gave the company an “equal weight” rating in a research report on Friday. Finally, Weiss Ratings upgraded Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $638.27.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 21,966 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the transaction, the chief executive officer owned 338,225 shares in the company, valued at approximately $211,549,590.75. This represents a 6.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 336,140 shares of company stock worth $208,008,328. 20.50% of the stock is currently owned by insiders.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Raised 2026 outlook: Medpace now expects full-year EPS of $17.97–$18.32, above the $17.68 analyst consensus. Revenue guidance of $2.8–$2.9 billion is also at or above expectations. Medpace forecasts 2026 EPS and buyback
• Positive Sentiment: Quarterly results exceeded expectations: Third-quarter EPS was $4.84 versus the $4.44 consensus, while revenue rose 8.5% year over year to $716 million, slightly ahead of forecasts. Net margin was 18.24%. Medpace third-quarter 2026 results
• Positive Sentiment: Demand indicators remained healthy: Third-quarter net new business awards reached $873 million, and ending backlog grew 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace three key takeaways
• Positive Sentiment: $1 billion buyback: The new authorization replaces the prior program and signals management confidence while potentially supporting per-share results. Medpace buyback and third-quarter profit
• Neutral Sentiment: Deutsche Bank raised its price target to $650 from $535 but retained a Hold rating, indicating improved fundamentals may already be reflected in the share price. Deutsche Bank Medpace price target
• Negative Sentiment: Investors remain concerned that Medpace is expensive, with commentary suggesting the stock may be about 24% overvalued. Those concerns help explain why the shares decreased even after the earnings beat and raised outlook. Medpace valuation analysis

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.